Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent

Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of
      Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer

PR Newswire

LAUSANNE, Switzerland, December 7, 2012

LAUSANNE, Switzerland, December 7, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group
of companies with a focus on the development of prescription drugs that target
unmet medical needs and companion diagnostics, announces that Dr.Reddy's
Laboratories Ltd. launched Pamorelin® LA in India for the treatment of locally
advanced or metastatic, hormone-dependent prostate cancer on December 3.

Under the terms of the agreement, Dr.Reddy's acquires exclusive marketing and
sales rights for Pamorelin® LA Depot in India. The product is exported in bulk
from Debio Recherche Pharmaceutique (Debio R.P.) to Dr.Reddy's. Pamorelin® LA
will be made available primarily to urologists and oncologists across India.

'We recognise the need for prostate cancer treatment in India and are thrilled
to have the opportunity to bring Pamorelin® LA to Indian patients', said
Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. 'This
major step enables us to implement our strategy in one of the most important
markets in Asia. This is only the logical continuation to a harmonious working
relationship shared with Dr.Reddy's over the years.' Dr.Reddy's and
Debiopharm share the same vision to bring high-quality and safe ethical
products to the highest number of patients suffering from serious diseases in
India.

About Pamorelin® LA (active ingredient: triptorelin)

Triptorelin is an agonist analogue of the natural gonadotropin-releasing
hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for
triptorelin with Tulane University in the US. Debiopharm has then developed
three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate.
The 1- and 3-month-formulations have been registered in most countries and are
currently available under the names of Trelstar® in North America, Decapeptyl®
/Pamorelin® in Europe and Latin America and from now on, of Pamorelin® in
India. The 6-month-formulation has been registered and is available in Europe
and the US.

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group
of companies with a focus on the development of prescription drugs that target
unmet medical needs. The group in-licenses, develops and/or co-develops
promising biological and small molecule drug candidates having reached
clinical development phases I, II or III, as well as earlier stage candidates.
It develops its products for global registration and maximum commercial
potential. The products are out-licensed to pharmaceutical partners for sales
and marketing. Debiopharm is also active in the field of companion diagnostics
with a view to progressing in the area of personalised medicine. Debiopharm
independently funds the worldwide development of all of its products while
providing expertise in pre-clinical and clinical trials, manufacturing, drug
delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit:
http://www.debiopharm.com.

About Debio R.P.

Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny (Switzerland),
is a pharmaceutical research, development and production company that has been
Swissmedic and ANVISA (Brazil) certified, as well as inspected and registered
by the American Food and Drug Administration (FDA) and the KFDA (South Korea).
Debio R.P. is active in the discovery, formulation and development of
peptides. Debio R.P. forms part of Debiopharm Group™ and employs 130 people,
half of whom are university graduates or engineers.

About Dr.Reddy's


Dr.Reddy's Laboratories Ltd. (NYSE: RDY) (Dr.Reddy's) is an integrated
global pharmaceutical company, committed to providing affordable and
innovative medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products - Dr.Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars,
differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain management,
anti-infective and pediatrics. Major markets include India, USA, Russia and
CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand.

For more information, log on to: http://www.drreddys.com

DebiopharmS.A.Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com

Dr.Reddy' s Contact
S. Rajan
rajans@drreddys.com
Tel.: +91-40-49002445
Additional Media Contacts
InLondon
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk

InNew York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com

Investors and Financial Analysts:
Kedar Upadhye
kedaru@drreddys.com
Tel.: +91-40-66834297

Saunak Savla
saunaks@drreddys.com
Tel.: +91-40-49002135

Milan Kalawadia (USA)
mkalawadia@drreddys.com
Tel.: +1-908-203-4931

SOURCE The Debiopharm Group